Abvc Biopharma, Inc. (ABVC) — SEC Filings
Abvc Biopharma, Inc. (ABVC) — 50 SEC filings. Latest: 10-Q (Nov 3, 2025). Includes 22 8-K, 11 8-K/A, 6 10-Q.
View Abvc Biopharma, Inc. on SEC EDGAR
Overview
Abvc Biopharma, Inc. (ABVC) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 3, 2025: ABVC BioPharma, Inc. reported a significant increase in total assets to $21,176,299 as of September 30, 2025, up from $7,539,907 at December 31, 2024, primarily driven by a substantial increase in property and equipment, net, to $12,055,642 from $511,088. Revenues for the nine months ended September
Sentiment Summary
Across 50 filings, the sentiment breakdown is: 3 bearish, 46 neutral, 1 mixed. The dominant filing sentiment for Abvc Biopharma, Inc. is neutral.
Filing Type Overview
Abvc Biopharma, Inc. (ABVC) has filed 6 10-Q, 22 8-K, 11 8-K/A, 1 DEF 14A, 2 10-K, 2 SC 13G/A, 1 S-1, 1 DEFA14A, 3 S-1/A, 1 10-K/A with the SEC between Feb 2024 to Nov 2025.
Filings by Year
Recent SEC Filings (50)
Risk Profile
Risk Assessment: Of ABVC's 47 recent filings, 3 were flagged as high-risk, 27 as medium-risk, and 17 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $795,950 |
| Net Income | -$4,564,546 |
| EPS | N/A |
| Debt-to-Equity | 0.46 |
| Cash Position | $192,068 |
| Operating Margin | N/A |
| Total Assets | $21,176,299 |
| Total Debt | $809,103 |
Key Executives
- Shuling Jiang
- Dr. Jian-Fu Chen
- Dr. Terence W. Li
- Dr. Uttam Patil
Industry Context
ABVC BioPharma operates in the competitive biotechnology sector, focusing on plant-derived drugs and medical devices. The industry is characterized by long development cycles, high R&D costs, and significant regulatory hurdles. Companies like ABVC rely on licensing technologies from research institutions and conducting extensive clinical trials to advance their pipelines.
Top Tags
amendment (11) · material-agreement (9) · filing (7) · 10-Q (5) · biopharma (5) · equity-sale (4) · financial-reporting (4) · quarterly-report (4) · SEC Filing (4) · financial-condition (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Total Assets | $21,176,299 | Increased from $7,539,907 at December 31, 2024, representing a 180% increase. |
| Property and equipment, net | $12,055,642 | Increased significantly from $511,088 at December 31, 2024, indicating major capital investment. |
| Revenues | $795,950 | For the nine months ended September 30, 2025, up from $507,623 in the prior year period. |
| Net loss | $4,564,546 | For the nine months ended September 30, 2025, an increase from $4,462,510 in the prior year period. |
| Stock-based compensation | $2,756,603 | For the nine months ended September 30, 2025, up from $2,410,381 in the prior year period. |
| Net cash used in operating activities | $1,567,264 | For the nine months ended September 30, 2025, an increase from $1,107,011 in the prior year period. |
| Due from related parties | $2,694,743 | Increased from $1,155,051 at December 31, 2024. |
| Shares of common stock outstanding | 24,301,089 | As of October 30, 2025, indicating potential dilution from 13,868,484 shares at December 31, 2024. |
| Accumulated deficit | $73,295,417 | Increased from $68,949,807 at December 31, 2024, reflecting ongoing losses. |
| Total Equity | $14,492,707 | Increased from $723,959 at December 31, 2024, largely due to noncontrolling interest and additional paid-in capital. |
| Total Stockholders' Equity | $9,489,733 | Increased from $723,959 at December 31, 2024, largely due to the land acquisition and private offerings. |
| Acquiring control of the land | $7,670,000 | Non-cash financing activity contributing to asset growth and noncontrolling interest. |
| Proceeds from private offerings | $1,868,750 | Cash provided by financing activities for the six months ended June 30, 2025. |
| Net cash provided by financing activities | $2,356,083 | For the six months ended June 30, 2025, essential for funding operations given negative cash flow from operations. |
| SEC File Number | 001-40700 | Identifies the company's filings with the SEC. |
Forward-Looking Statements
- {"claim":"ABVC Biopharma will likely proceed with a capital raise in the near future.","entity":"ABVC BIOPHARMA, INC.","targetDate":"2024-12-31","confidence":"medium"}
- {"claim":"ABVC Biopharma's stock price will experience volatility as investors await details on the material agreement and assess the impact of equity dilution.","entity":"ABVC BIOPHARMA, INC.","targetDate":"2024-03-08","confidence":"medium"}
Frequently Asked Questions
What are the latest SEC filings for Abvc Biopharma, Inc. (ABVC)?
Abvc Biopharma, Inc. has 50 recent SEC filings from Feb 2024 to Nov 2025, including 22 8-K, 11 8-K/A, 6 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of ABVC filings?
Across 50 filings, the sentiment breakdown is: 3 bearish, 46 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Abvc Biopharma, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Abvc Biopharma, Inc. (ABVC) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Abvc Biopharma, Inc.?
Key financial highlights from Abvc Biopharma, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for ABVC?
The investment thesis for ABVC includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Abvc Biopharma, Inc.?
Key executives identified across Abvc Biopharma, Inc.'s filings include Shuling Jiang, Dr. Jian-Fu Chen, Dr. Terence W. Li, Dr. Uttam Patil.
What are the main risk factors for Abvc Biopharma, Inc. stock?
Of ABVC's 47 assessed filings, 3 were flagged high-risk, 27 medium-risk, and 17 low-risk.
What are recent predictions and forward guidance from Abvc Biopharma, Inc.?
Recent forward-looking statements from Abvc Biopharma, Inc. include guidance on {"claim":"ABVC Biopharma will likely proceed with a capital raise in the near future.","entity":"ABVC BIOPHARMA, INC."," and 1 other predictions.